00874.HK
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 13.51
+0.97%Year over year
Reported trailing growth
- Revenue
- +2.4%
- EBITDA
- -4.9%
- EBIT
- -14.6%
- EPS
- -8.7%
- Free cash flow
- +917.5%
- Operating cash flow
- +200.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +3.1%
- EBITDA
- -14.0%
- EBIT
- -10.6%
- Net income
- -9.1%
- EPS
- -9.1%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026